Related Experiment Video
Updated: Jul 19, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Cancer research training: the Southwest Oncology Group young investigator training program (YITP)
Zeina Nahleh1, Rami Komrokji, Abdul-Rahman Jazieh
1Department of Internal Medicine, Division of Hematology-Oncology, University of Cincinnati, USA. nalehza@ucmail.uc.edu
Background:
Recognizing the growing need for an infusion of new investigators into the cancer researchers, and realizing that well-trained cancer researchers are a dying breed, the Southwest Oncology Group (SWOG) initiated the Young Investigator Training Program (YITP) in 1999, supported by the Hope Foundation. The first author was one of four applicants accepted in 2004 and is reporting on this experience.
Methods:
After a rigorous and competitive application process, four physicians beginning their career in Hematology-Oncology are chosen each year. Each investigator would have submitted an original research concept. Each class receives intensive training in statistical principles, data collection and analysis, critical decision making, and protocol development guidelines. Each investigator spends 4 days at the SWOG operations office in San Antonio, Texas, and 4 days at the statistical center in Seattle, Washington.
Results:
As part of the training course, each investigator will design a clinical protocol that will be reviewed by the appropriate disease committees within SWOG. Once approved, it will be submitted to the National Cancer Institute for further review. The four investigators will receive a certificate at the successful completion of the training course and will be recognized at the group meeting. With the class of 2004, 31 investigators will have joined the ranks of seasoned researchers. Fifteen protocols have been introduced and activated at institutions across the United States. Four other protocols are in various stages of the development and approval process.
Conclusion:
The Hope Foundation sponsored SWOG YITP is a unique opportunity. It allows participants to acquire a thorough understanding of the conduct of cancer clinical trials through SWOG. Large institutions are urged to continue sponsoring similar programs. This will build an infrastructure of well-trained cancer researchers to foster and continue the progress achieved in cancer research.
Insights
The Southwest Oncology Group (SWOG) Young Investigator Training Program (YITP) trains new cancer researchers in clinical trial development. This program has successfully trained 31 investigators and activated 15 clinical protocols.
Area of Science:
- Oncology
- Clinical Trials
- Medical Education
Background:
- Addressing a decline in trained cancer researchers.
- Southwest Oncology Group (SWOG) established the Young Investigator Training Program (YITP) in 1999.
- The Hope Foundation provides financial support for the YITP.
Purpose of the Study:
- To describe the SWOG Young Investigator Training Program (YITP).
- To evaluate the program's impact on training new cancer researchers.
- To encourage continued support for similar initiatives.
Main Methods:
- Rigorous selection of four Hematology-Oncology physicians annually.
- Intensive training in statistical principles, data collection, analysis, and protocol development.
- Hands-on experience designing clinical protocols within SWOG.
Main Results:
- 31 investigators trained by the class of 2004.
- 15 clinical protocols introduced and activated across the U.S.
- Four additional protocols are in development and approval stages.
Conclusions:
- The SWOG YITP offers a unique opportunity to learn cancer clinical trial conduct.
- The program successfully builds an infrastructure of skilled cancer researchers.
- Continued sponsorship of similar programs is crucial for advancing cancer research.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
